Why MannKind Stock Soared 19% Higher on Tuesday
Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a day when the S 500 index slumped by 0.4%.
The reason for the stock's jump wasn't hard to tease out.
MannKind, which concentrates on developing treatments for endocrine and lung disorders, published its second quarter results that day.
Source Fool.com
MannKind Corp. Aktie
3,32 €
0,12 %
Die Community ist sich einig: MannKind Corp. nur mit Buy-Einschätzungen, keine Sell-Einschätzungen.
Für MannKind Corp. liegt das Community-Kursziel bei 7 €, was eine erhebliche Steigerung gegenüber dem aktuellen Kurs von 3.32 € darstellt.
